Jazz Pharmaceuticals
JAZZ
366 hedge funds and large institutions have $7.63B invested in Jazz Pharmaceuticals in 2016 Q2 according to their latest regulatory filings, with 73 funds opening new positions, 135 increasing their positions, 115 reducing their positions, and 41 closing their positions.
78% more first-time investments, than exits
New positions opened: 73 | Existing positions closed: 41
63% more call options, than puts
Call options by funds: $129M | Put options by funds: $79.4M
40% more funds holding in top 10
Funds holding in top 10: 10 → 14 (+4)
17% more repeat investments, than reductions
Existing positions increased: 135 | Existing positions reduced: 115
8% more funds holding
Funds holding: 339 → 366 (+27)
8% more capital invested
Capital invested by funds: $7.07B → $7.63B (+$554M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Viking Global Investors
Stamford,
Connecticut
|
+$91.2M |
| 2 |
Renaissance Technologies
New York
|
+$74.4M |
| 3 |
Millennium Management
New York
|
+$62.9M |
| 4 |
Two Sigma Investments
New York
|
+$58.7M |
| 5 |
Goldman Sachs
New York
|
+$54.8M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PI
Putnam Investments
Boston,
Massachusetts
|
-$336M |
| 2 |
BFA
BlackRock Fund Advisors
San Francisco,
California
|
-$77.8M |
| 3 |
State Street
Boston,
Massachusetts
|
-$74.2M |
| 4 |
BIT
BlackRock Institutional Trust
San Francisco,
California
|
-$60.7M |
| 5 |
HCM
Herndon Capital Management
Atlanta,
Georgia
|
-$38.8M |
JAZZ Hedge Fund Activity: Q2 2016 in Review
366 of the 3,748 institutional investors tracked by Wall St. Rank reported a position in Jazz Pharmaceuticals (JAZZ) for Q2 2016, worth a combined $7.63B — up 7.8% from $7.07B a quarter earlier.
Buyers outnumbered sellers: 73 funds opened new JAZZ positions and 41 closed out — a net gain of 32 holders — while 135 added to existing stakes and 115 trimmed.
The largest buyer was Viking Global Investors, opening a new position worth an estimated $91.2M. The largest seller was Putnam Investments, cutting an estimated $336M.
- 366 institutional investors held Jazz Pharmaceuticals (JAZZ) as of Q2 2016, up from 339 in Q1 2016.
- Funds reported $7.63B of Jazz Pharmaceuticals stock for Q2 2016, up 7.8% quarter-over-quarter.
- 73 funds opened new Jazz Pharmaceuticals positions in Q2 2016 and 41 closed out, a net change of +32 holders.
- The largest Jazz Pharmaceuticals buyer in Q2 2016 was Viking Global Investors, an estimated $91.2M added.
- The largest Jazz Pharmaceuticals seller in Q2 2016 was Putnam Investments, an estimated $336M sold.
Based on aggregated 13F filings for Q2 2016.